Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature - Quiz - MDSpire

Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature

  • By

  • Weige Xu

  • Xue Qiao

  • Linlin Zhang

  • Lina Xing

  • Jingnan Zhang

  • Xiaonan Guo

  • Shukai Qiao

  • April 28, 2026

  • 0 min

Share

Original Source(s)

Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature

  • by Weige Xu, Xue Qiao, Linlin Zhang, Lina Xing, Jingnan Zhang, Xiaonan Guo, Shukai Qiao

  • April 28, 2026

Related Content

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

High-grade astrocytoma with piloid features: a case report of comprehensive management